PharmaCyte Biotech, Inc. provided an update on its investigation of its Cell-in-a-Box technology and initial next steps in development. Following a comprehensive scientific review of amassed data, the Company is in the process of requesting a meeting with the U.S. Food and Drug Administration (FDA) for guidance on further development of the technology. The meeting is expected to occur during the first quarter of 2024.

In the meantime, the Company is reviewing multiple potential opportunities that it believes would be prudent uses for its approximately $74.6 million cash position as of July 31, 2023, which was previously reported in the Company?s Quarterly Report on Form 10-Q filed on September 18, 2023.